Curexo Inc (060280) Fair Value & Analysis
Consumer Non-Cyclicals · KR · Market cap 339B KRW
Fair value as of: Jul 22, 2026
From 15 valuation models · updated 18 days ago
Fair value updated Jul 22, 2026, revised from 1,412 KRW to 1,147 KRW (−18.8%) since Jul 6, 2026. Share price +7.9% over the past month.
A solid business, but screening 87% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (1,433 KRW). The favourable scenario is already priced in.
- Solid but not exceptional quality (59/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 5,610 KRW – 24,400 KRW · fair‑value band 859.98 KRW – 1,433 KRW · the 8,780 KRW price screens above the 1,147 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Curexo Inc (060280) currently trades at 8,780 KRW, while our model-based Fair Value estimate is 1,147 KRW, implying the stock looks roughly 86.9% overvalued today. The Quality Score stands at 59/100 (solid quality), in the Consumer Non-Cyclicals sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Curexo Inc generated revenue of 27.8B KRW at a net margin of -58.0%. Revenue grew 4.3% year over year. Net debt stands at 5.2B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 859.98 KRW (bear case) to 1,433 KRW (bull case); at 8,780 KRW, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 61% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Non-Cyclicals peers we cover trades at -18% fair-value upside, at -87%, 060280 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 15 models by family
Widest divergence: DCF Models (3,292 KRW) versus Earnings-Based (1,248 KRW). Highest evidence: ROIC Compounder (72).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 19
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Curexo Inc. engages in the development and sale of medical devices in Korea and internationally. Its products include ROBIN, a robot system that guides needle path induring CT-guided interventional procedure; Baidy, a medical device that assists labor by increasing intrauterine pressure which helps natural childbirth; artificial joint surgical robot; and …
Full company description
Curexo Inc. engages in the development and sale of medical devices in Korea and internationally. Its products include ROBIN, a robot system that guides needle path induring CT-guided interventional procedure; Baidy, a medical device that assists labor by increasing intrauterine pressure which helps natural childbirth; artificial joint surgical robot; and Gait rehabilitation robot. The company also imports, distributes, and sells food and food additives. Curexo Inc. was founded in 2006 and is headquartered in Seoul, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Curexo Inc reported revenue of 74.5B KRW in FY2025 versus 42.8B KRW in FY2021, a compound +14.9%/yr. Reported net income was 2.8B KRW in FY2025.
060280 screens 87% overvalued. Compare with PGOLD →
Peer Group
Health Care · 2228 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Food & Drug Retailing” was too small, so the broader sector is used.)
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Food & Drug Retailing stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| PGOLD PGOLD | 39.30 PHP | 62.75 PHP | +60% |
| RRHI RRHI | 38.00 PHP | 43.51 PHP | +15% |
| KEEPR KEEPR | 1.86 PHP | 6.15 PHP | +231% |
| Gimat Magazacilik Sanayi Ve Ticaret A.S. GMTAS | 46.70 TRY | 8.96 TRY | -81% |
| FRUIT FRUIT | 0.6700 PHP | 0.5500 PHP | -18% |
| Seouleaguer Co 043710 | 2,850 KRW | 811.29 KRW | -72% |
| COSCO COSCO | ₹208.00 | ₹51.24 | -75% |
| FB FB | 49.00 PHP | 49.03 PHP | +0% |
| JGS JGS | 25.00 PHP | 20.51 PHP | -18% |
| URC URC | 61.20 PHP | 47.86 PHP | -22% |
Compare Curexo Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
Frequently asked questions
Is Curexo Inc (060280) overvalued or undervalued?
What is the fair value of 060280?
What is the quality score of 060280?
What is the revenue of Curexo Inc (060280)?
What is the net profit margin of 060280?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Curexo Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.